Analyst Reco. Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-08 pm EST			5-day change	1st Jan Change
24.42 ^USD	+1.79%		+3.61%	+29.62%

Dec. 03	Pacira Biosciences reports inducement grants under Nasdaq Listing Rule	RE
Dec. 02	Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain	MT

Analyst Reco.

Pacira BioSciences' Q2 revenue misses estimates	Aug. 05	RE
Pacira Biosciences Shares Rise After Upgrade From Truist	Jul. 25	MT
Truist Upgrades Pacira Biosciences to Buy From Hold, Raises Price Target to $30 From $28	Jul. 25	MT
RBC Raises Price Target on Pacira Biosciences to $26 From $22, Keeps Sector Perform Rating	Apr. 08	MT
Truist Raises Price Target on Pacira Biosciences to $28 From $25, Keeps Hold Rating	Apr. 08	MT
RBC Capital Adjusts Pacira Biosciences Price Target to $22 From $18, Maintains Sector Perform Rating	Feb. 28	MT
Truist Upgrades Pacira Biosciences to Hold From Sell, Boosts Price Target to $25 From $8	Jan. 30	MT
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating	Jan. 07	MT
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating	Nov. 07	MT
RBC Raises Price Target on Pacira BioSciences to $15 From $14, Keeps Sector Perform Rating	24-10-04	MT
Jefferies & Co Adjusts Pacira BioSciences Price Target to $18 From $15, Maintains Buy Rating	24-09-24	MT
Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30	24-08-13	MT
RBC Capital Downgrades Pacira BioSciences to Sector Perform From Outperform, Cuts Price Target to $14 From $37	24-08-12	MT
RBC Downgrades Pacira BioSciences to Sector Perform From Outperform, Adjusts Price Target to $14 From $37	24-08-12	MT
JPMorgan Downgrades Pacira BioSciences to Underweight From Overweight, Adjusts Price Target to $10 From $45	24-08-12	MT
Raymond James Downgrades Pacira BioSciences to Market Perform From Outperform	24-08-12	MT
Piper Sandler Downgrades Pacira BioSciences to Neutral From Overweight, Adjusts Price Target to $11 From $42	24-08-12	MT
RBC Lowers Price Target on Pacira BioSciences to $37 From $42, Keeps Outperform Rating	24-07-31	MT
Truist Cuts Price Target on Pacira BioSciences to $30 From $45, Keeps Buy Rating	24-07-25	MT
RBC Cuts Price Target on Pacira BioSciences to $42 From $45, Keeps Outperform Rating	24-07-09	MT
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38	24-07-03	MT
Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating	24-05-08	MT
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	24-03-01	MT
RBC Cuts Price Target on Pacira BioSciences to $53 From $58, Keeps Outperform Rating	24-01-03	MT
Raymond James Initiates Pacira BioSciences With Outperform Rating, Price Target is $42	23-12-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Analyst Reco.

Filters